|
animals |
14 |
|
cell proliferation |
14 |
|
humans |
14 |
|
ovarian cancer |
13 |
|
female |
12 |
|
cell line, tumor |
11 |
|
metastasis |
11 |
|
hepatocellular carcinoma |
10 |
|
brca1 |
9 |
|
cell movement |
9 |
|
ascitic fluid |
8 |
|
carcinoma/metabolism |
8 |
|
carcinoma/secondary |
8 |
|
cell adhesion |
8 |
|
adolescent |
7 |
|
adult |
7 |
|
aged |
7 |
|
cancer metastasis |
7 |
|
carcinoma, hepatocellular - genetics - mortality - secondary |
7 |
|
caveolin 1 - genetics - metabolism |
7 |
|
caveolin-1 |
7 |
|
clone cells |
7 |
|
disease models, animal |
7 |
|
disease progression |
7 |
|
gene knockdown techniques |
7 |
|
gene silencing |
7 |
|
hong kong - epidemiology |
7 |
|
liver - metabolism - pathology |
7 |
|
liver neoplasms - genetics - mortality - pathology |
7 |
|
male |
7 |
|
mice |
7 |
|
mice, inbred balb c |
7 |
|
mice, nude |
7 |
|
middle aged |
7 |
|
neoplasm transplantation |
7 |
|
p-cadherin |
7 |
|
survival rate |
7 |
|
tumourigenesis |
7 |
|
up-regulation |
7 |
|
young adult |
7 |
|
adhesion |
6 |
|
brca1 protein - genetics |
6 |
|
brca2 |
6 |
|
brca2 protein - genetics |
6 |
|
breast cancer susceptibility gene |
6 |
|
breast neoplasms - genetics - pathology |
6 |
|
checkpoint inhibitor |
6 |
|
epigenetic |
6 |
|
gene mutation |
6 |
|
genetic predisposition to disease - genetics |
6 |
|
immunotherapy |
6 |
|
neoplasms |
6 |
|
nuclear factor kappa b |
6 |
|
nuclear met |
6 |
|
open reading frames - genetics |
6 |
|
p70 s6 kinase |
6 |
|
transforming growth factor beta-activated kinase 1 |
6 |
|
antigens, polyomavirus transforming - genetics |
5 |
|
breast cancer |
5 |
|
cell culture techniques - methods |
5 |
|
endometrium |
5 |
|
epithelial cells - cytology - metabolism |
5 |
|
genitalia, female - cytology |
5 |
|
in situ nick-end labeling |
5 |
|
in vitro culture |
5 |
|
ovary |
5 |
|
oviduct |
5 |
|
reproduction |
5 |
|
reverse transcriptase polymerase chain reaction |
5 |
|
3d culture |
4 |
|
antibodies - pharmacology |
4 |
|
antimetastasis |
4 |
|
autophagy |
4 |
|
bioengineering |
4 |
|
cadherins - antagonists and inhibitors - genetics - physiology |
4 |
|
cancer stem cells |
4 |
|
carcinoma - genetics - pathology |
4 |
|
catenins - genetics - metabolism - physiology |
4 |
|
cell differentiation |
4 |
|
cell division - drug effects |
4 |
|
cell line |
4 |
|
cell line, transformed |
4 |
|
co-culture |
4 |
|
enzyme activation |
4 |
|
epithelial cells - pathology |
4 |
|
estradiol - pharmacology |
4 |
|
eye proteins - antagonists & inhibitors - genetics - pharmacology |
4 |
|
gene expression |
4 |
|
gene expression - drug effects |
4 |
|
gene expression data analysis |
4 |
|
gene expression profiling - methods |
4 |
|
gnrh |
4 |
|
igf-1r |
4 |
|
immunohistochemistry |
4 |
|
issue 120 |
4 |
|
least-squares analysis |
4 |
|
map kinase signaling system - drug effects |
4 |
|
medical sciences |
4 |
|
metabolism |
4 |
|
microfluidics |
4 |
|
missing value imputation |
4 |
|
motility |
4 |
|
multicellular spheroids |
4 |
|
n-heterocyclic carbene |
4 |
|
nerve growth factors - antagonists & inhibitors - genetics - pharmacology |
4 |
|
oligonucleotide array sequence analysis - methods |
4 |
|
ovarian neoplasms - genetics - pathology |
4 |
|
ovarian neoplasms - pathology |
4 |
|
ovary - pathology |
4 |
|
p120ctn |
4 |
|
p70s6k |
4 |
|
peritoneal adhesion |
4 |
|
peritoneal mesothelial cells |
4 |
|
platinum |
4 |
|
polymerase chain reaction |
4 |
|
receptor, igf type 1 - antagonists and inhibitors - genetics - physiology |
4 |
|
rna, messenger - analysis |
4 |
|
rna, small interfering - pharmacology |
4 |
|
serpins - genetics - pharmacology |
4 |
|
shear stress |
4 |
|
survival |
4 |
|
vector angle |
4 |
|
vimentin |
4 |
|
weighted local least square imputation |
4 |
|
wllsi |
4 |
|
β1 integrin |
4 |
|
2-methoxyestradiol |
3 |
|
actin |
3 |
|
actins - metabolism - ultrastructure |
3 |
|
algorithms |
3 |
|
angiogenesis |
3 |
|
angiogenesis inducing agents - pharmacology |
3 |
|
bacteria |
3 |
|
cancer nanomedicine |
3 |
|
cdc42 |
3 |
|
cell signaling |
3 |
|
cell-to-cell contact |
3 |
|
chromatin |
3 |
|
cytoskeleton - metabolism - ultrastructure |
3 |
|
dendrimer nanovector |
3 |
|
dna |
3 |
|
dose-response relationship, drug |
3 |
|
drops |
3 |
|
edcs |
3 |
|
emulsification |
3 |
|
emulsions |
3 |
|
endoreduplication |
3 |
|
endothelial cells |
3 |
|
endothelial cells - drug effects - metabolism |
3 |
|
enos |
3 |
|
environmental radiation |
3 |
|
epithelial cells - metabolism - pathology |
3 |
|
epr effect |
3 |
|
estradiol - analogs & derivatives - pharmacology |
3 |
|
gene regulatory networks |
3 |
|
ginseng |
3 |
|
ginsenosides - pharmacology |
3 |
|
huvec |
3 |
|
local least squares imputation method |
3 |
|
mapk signaling pathways |
3 |
|
mesoderm - metabolism - pathology |
3 |
|
microarray data |
3 |
|
migration |
3 |
|
missing values |
3 |
|
mitochondria |
3 |
|
mitochondria - drug effects - metabolism |
3 |
|
mitogen-activated protein kinase 1 - metabolism |
3 |
|
mitogen-activated protein kinase 3 - metabolism |
3 |
|
models, genetic |
3 |
|
models, statistical |
3 |
|
nasopharyngeal carcinoma |
3 |
|
neovascularization, physiologic - drug effects |
3 |
|
non-viral delivery |
3 |
|
oestrogen receptor |
3 |
|
oncology |
3 |
|
optical trapping |
3 |
|
ovarian |
3 |
|
ovarian neoplasms - genetics - metabolism - pathology |
3 |
|
oxidative stress |
3 |
|
oxidative stress - drug effects |
3 |
|
paclitaxel - pharmacology |
3 |
|
pedf |
3 |
|
pi3k/akt |
3 |
|
pollutants |
3 |
|
postnatal expression |
3 |
|
protein micropillar matrix |
3 |
|
rac1 |
3 |
|
receptor cross-talk - drug effects |
3 |
|
reproductive functions |
3 |
|
reproductive impairments |
3 |
|
ribosomal protein s6 kinases, 70-kda - genetics - metabolism |
3 |
|
ribosomal protein s6 kinases, 70-kda - physiology |
3 |
|
rna, small interfering - genetics |
3 |
|
rnai therapy |
3 |
|
row average method |
3 |
|
sex hormone binding globulin |
3 |
|
signaling |
3 |
|
signaling pathway |
3 |
|
signalling |
3 |
|
sirna delivery |
3 |
|
systems biology - methods |
3 |
|
targeted therapy |
3 |
|
testicular |
3 |
|
traction-force microscopy |
3 |
|
transfection |
3 |
|
truncated shbg |
3 |
|
tubulin modulators - pharmacology |
3 |
|
weighted local least squares imputation method |
3 |
|
5-aza-2′-deoxycytidine |
2 |
|
aflatoxin b1 |
2 |
|
afm indentation |
2 |
|
anoikis - drug effects - physiology |
2 |
|
antineoplastic agents - pharmacology |
2 |
|
antioxidants - pharmacology |
2 |
|
apoptosis |
2 |
|
apoptosis - drug effects - physiology |
2 |
|
ascites cell |
2 |
|
base sequence |
2 |
|
blotting, western |
2 |
|
boolean networks |
2 |
|
cadherin |
2 |
|
cadherins - genetics - metabolism |
2 |
|
cadherins - physiology |
2 |
|
cancer associated fibroblast |
2 |
|
caspase 9 - antagonists & inhibitors - genetics - metabolism |
2 |
|
caspases |
2 |
|
catenins - physiology |
2 |
|
cell component |
2 |
|
cell movement - drug effects |
2 |
|
cell movement - drug effects - physiology |
2 |
|
cell transformation, neoplastic |
2 |
|
chemotherapy |
2 |
|
chip |
2 |
|
cisplatin - pharmacology |
2 |
|
clinical article |
2 |
|
cpg island |
2 |
|
cross-talk |
2 |
|
dna methyltransferase 1 |
2 |
|
down-regulation - drug effects |
2 |
|
doxorubicin - pharmacology |
2 |
|
drug resistance, neoplasm - physiology |
2 |
|
dynamic programming |
2 |
|
elastic modulus |
2 |
|
endocrine disruptor |
2 |
|
endocrine system |
2 |
|
endothelial cells - metabolism |
2 |
|
enzyme activation - drug effects |
2 |
|
enzyme activation - drug effects - physiology |
2 |
|
enzyme induction - drug effects |
2 |
|
epithelial mesenchymal transition |
2 |
|
estrogen receptor alpha - metabolism |
2 |
|
estrogen receptor beta - metabolism |
2 |
|
extrapituitary |
2 |
|
finite-element modelling |
2 |
|
finite-horizon |
2 |
|
g protein-coupled receptor |
2 |
|
gene expression regulation - drug effects |
2 |
|
genetic predisposition to disease |
2 |
|
genetics |
2 |
|
ginsenoside |
2 |
|
ginsenosides - isolation and purification - pharmacology |
2 |
|
gnrh receptor |
2 |
|
gonadotropin-releasing hormone - pharmacology |
2 |
|
gonadotropin-releasing hormone - physiology |
2 |
|
hepatocyte growth factor - metabolism |
2 |
|
hif-1α |
2 |
|
hydralazine |
2 |
|
hypoxia |
2 |
|
hypoxia-inducible factor 1, alpha subunit - genetics - metabolism |
2 |
|
intervention |
2 |
|
invasion |
2 |
|
jnk mitogen-activated protein kinases - metabolism |
2 |
|
mapk |
2 |
|
markov chain |
2 |
|
matrix metalloproteinase 2 - antagonists & inhibitors - biosynthesis - genetics - metabolism |
2 |
|
matrix metalloproteinase 9 - antagonists & inhibitors - biosynthesis - genetics - metabolism |
2 |
|
matrix metalloproteinases |
2 |
|
microrna |
2 |
|
mixture |
2 |
|
mnsod |
2 |
|
monomers |
2 |
|
neoplasm invasiveness |
2 |
|
neovascularization, physiologic - physiology |
2 |
|
oligopeptides - pharmacology |
2 |
|
optimal control |
2 |
|
ovarian cells |
2 |
|
ovarian neoplasms - drug therapy - enzymology - genetics |
2 |
|
ovarian neoplasms - enzymology - genetics - pathology |
2 |
|
ovarian neoplasms - genetics - metabolism - physiopathology - secondary |
2 |
|
ovarian neoplasms - metabolism |
2 |
|
ovaries -- cancer. |
2 |
|
panax - chemistry |
2 |
|
peptide hormone |
2 |
|
peptides and proteins |
2 |
|
phosphatidylinositol 3-kinases - metabolism |
2 |
|
pi3k |
2 |
|
pituitary |
2 |
|
probabilistic boolean networks |
2 |
|
proliferation |
2 |
|
promoter regions, genetic - drug effects |
2 |
|
proto-oncogene proteins c-met - metabolism |
2 |
|
ras proteins - metabolism |
2 |
|
reactive oxygen species - metabolism |
2 |
|
receptor cross-talk - drug effects - physiology |
2 |
|
receptor tyrosine kinase |
2 |
|
receptors, lhrh - biosynthesis - genetics |
2 |
|
rna interference |
2 |
|
rna, messenger - biosynthesis - genetics |
2 |
|
signal transduction - drug effects |
2 |
|
signal transduction - drug effects - physiology |
2 |
|
signal transduction - physiology |
2 |
|
superoxide dismutase - antagonists & inhibitors - genetics - metabolism |
2 |
|
transcription factors - antagonists & inhibitors - genetics - metabolism |
2 |
|
tumor |
2 |
|
up-regulation - drug effects |
2 |
|
abcg2 |
1 |
|
antigens, polyomavirus transforming - genetics - physiology |
1 |
|
ap-1 |
1 |
|
autocrine communication |
1 |
|
b-catenin |
1 |
|
beta catenin - agonists - genetics - physiology |
1 |
|
beta catenin - genetics - metabolism |
1 |
|
beta catenin - metabolism |
1 |
|
bile acid |
1 |
|
biological agents - therapeutic use |
1 |
|
bisphenol a |
1 |
|
breast neoplasms |
1 |
|
c-kit |
1 |
|
ca-125 antigen - analysis |
1 |
|
cadherins - biosynthesis |
1 |
|
cadherins - biosynthesis - genetics |
1 |
|
cadherins - genetics |
1 |
|
cancer |
1 |
|
carbene |
1 |
|
carbenes |
1 |
|
carcinogenesis |
1 |
|
carcinoma |
1 |
|
carcinoma - pathology |
1 |
|
carcinoma, hepatocellular - genetics |
1 |
|
carcinoma, papillary - genetics - metabolism - pathology |
1 |
|
cell adhesion - physiology |
1 |
|
cell culture techniques |
1 |
|
cell membrane - metabolism |
1 |
|
cell migration |
1 |
|
cell motility |
1 |
|
cell movement - genetics |
1 |
|
cell transformation, neoplastic - metabolism |
1 |
|
cells, cultured |
1 |
|
central nervous system agents - pharmacology |
1 |
|
cervical cancer |
1 |
|
chemoresistance |
1 |
|
collagen |
1 |
|
collagen - metabolism |
1 |
|
collagen gel contraction |
1 |
|
colonic neoplasms - genetics - metabolism - pathology |
1 |
|
colorectal cancer |
1 |
|
compound k |
1 |
|
cyclin-dependent kinases - metabolism |
1 |
|
cyclooxygenase 2 - physiology |
1 |
|
differentiation |
1 |
|
dithiocarbamate |
1 |
|
drug combinations |
1 |
|
drug evaluation, preclinical |
1 |
|
drug synergism |
1 |
|
drug target identification |
1 |
|
e-cadherin |
1 |
|
electrophoresis, polyacrylamide gel |
1 |
|
emt |
1 |
|
endothelial cells - cytology - metabolism |
1 |
|
endothelium, vascular - cytology |
1 |
|
epidermal growth factor |
1 |
|
epidermal growth factor - pharmacology |
1 |
|
epithelial cells |
1 |
|
epithelial cells - cytology |
1 |
|
epithelial cells - drug effects - enzymology |
1 |
|
epithelial cells - immunology - pathology |
1 |
|
epithelial cells - metabolism |
1 |
|
epithelial ovarian cancer |
1 |
|
epithelio-mesenchymal transition |
1 |
|
epithelium - enzymology - pathology |
1 |
|
epithelium - pathology |
1 |
|
epithelium - pathology - physiology |
1 |
|
exosomes |
1 |
|
familial ovarian cancer |
1 |
|
genes, brca1 - genetics |
1 |
|
genomic |
1 |
|
germ cell |
1 |
|
glycogen synthase kinase 3 - metabolism |
1 |
|
gold |
1 |
|
gonadotropin |
1 |
|
gonadotropins - pharmacology |
1 |
|
growth factor |
1 |
|
grp78 |
1 |
|
hepatocyte growth factor |
1 |
|
hepatocyte growth factor - biosynthesis |
1 |
|
hepatocyte growth factor - pharmacology |
1 |
|
hepatocyte growth factor receptor |
1 |
|
hereditary |
1 |
|
hgf |
1 |
|
hormone |
1 |
|
human ovarian surface epithelium |
1 |
|
hybrid |
1 |
|
jnk |
1 |
|
kidney - cytology - drug effects |
1 |
|
laminin |
1 |
|
laminin - metabolism |
1 |
|
liver neoplasms - genetics |
1 |
|
matrix metalloproteinase 9 - metabolism |
1 |
|
medical history taking |
1 |
|
membrane proteins - agonists - antagonists & inhibitors - physiology |
1 |
|
met |
1 |
|
met oncogene |
1 |
|
metal-organic framework |
1 |
|
metal-organic frameworks |
1 |
|
metaplasia |
1 |
|
microfilament proteins - metabolism |
1 |
|
microrna biogenesis |
1 |
|
microscopy, fluorescence |
1 |
|
mitogen-activated protein kinase 1 - physiology |
1 |
|
mitogen-activated protein kinase 3 - physiology |
1 |
|
models, biological |
1 |
|
molecular pharmacology |
1 |
|
morphogenesis |
1 |
|
multicellular spheroid formation |
1 |
|
nasopharyngeal cancer |
1 |
|
neoplasm invasiveness - physiopathology |
1 |
|
neoplasms - metabolism |
1 |
|
neoplasms - metabolism - physiopathology |
1 |
|
non-genomic |
1 |
|
nuclear receptor subfamily 4, group a, member 1 - genetics - metabolism |
1 |
|
nuclear receptor subfamily 4, group a, member 1 - metabolism |
1 |
|
nur77 |
1 |
|
oestrogen receptors |
1 |
|
orphan nuclear receptor nur77 |
1 |
|
ose |
1 |
|
ovarian cancers |
1 |
|
ovarian neoplasms - drug therapy - metabolism |
1 |
|
ovarian neoplasms - enzymology - pathology |
1 |
|
ovarian neoplasms - etiology - genetics |
1 |
|
ovarian neoplasms - genetics - physiopathology |
1 |
|
ovarian neoplasms - metabolism - pathology |
1 |
|
ovarian surface epithelial cells |
1 |
|
ovarian surface epithelium |
1 |
|
ovary - cytology - drug effects - enzymology |
1 |
|
ovary - cytology - embryology - pathology |
1 |
|
ovary - cytology - metabolism |
1 |
|
ovary - enzymology - pathology |
1 |
|
ovary - immunology - pathology |
1 |
|
ovary - pathology - physiology |
1 |
|
p38 mitogen-activated protein kinases - metabolism - physiology |
1 |
|
pedigree |
1 |
|
pftk1 |
1 |
|
phosphorylation |
1 |
|
pi3k/akt inhibitors |
1 |
|
polyhydroxyethyl methacrylate |
1 |
|
precancerous conditions - enzymology - pathology |
1 |
|
protein |
1 |
|
protein kinase |
1 |
|
protein kinases - biosynthesis - metabolism |
1 |
|
proteoglycans |
1 |
|
proteoglycans - metabolism |
1 |
|
proto-oncogene proteins c-akt - metabolism |
1 |
|
proto-oncogene proteins c-met - biosynthesis |
1 |
|
receptors, glucocorticoid - metabolism |
1 |
|
ribosomal protein s6 kinases, 70-kda - antagonists and inhibitors - metabolism |
1 |
|
rna |
1 |
|
rna, messenger - biosynthesis |
1 |
|
rna, small interfering - genetics - pharmacology |
1 |
|
rna, small interfering - metabolism |
1 |
|
scattering |
1 |
|
signal transduction |
1 |
|
signaling networks |
1 |
|
spermatogenesis |
1 |
|
sprouty |
1 |
|
stem cells - cytology |
1 |
|
subcellular fractions - metabolism |
1 |
|
surface properties |
1 |
|
tagln2 |
1 |
|
tcf transcription factors - agonists - genetics - physiology |
1 |
|
tcf transcription factors - metabolism |
1 |
|
testis |
1 |
|
therapeutic target |
1 |
|
transcription, genetic - drug effects |
1 |
|
tumor cells, cultured |
1 |
|
tumor cells, cultured - drug effects |
1 |
|
unfolded protein response |
1 |
|
uterine cervical neoplasms - metabolism - pathology |
1 |
|
vascular endothelial growth factor a - biosynthesis - metabolism |
1 |
|
β-catenin |
1 |
